(Total Views: 611)
Posted On: 03/09/2021 1:17:03 AM
Post# of 148908
I got that from the call as well.
Needed more n, more critical patients, and a representative age distribution between drug and control arms.
Also thought I heard the new trial would be 1 to 1. Wondering if I heard that right and what the secondary endpoints would be.
Nader seems to be relying on Brian Brothen to help fill quickly. My take is the Mr Brothen did make a huge enrollment difference in November and December. Plus there is more data. So they may be able to fill quickly.
So I see some dark weeks coming where people complain about enrollment and worry about dilution. Good time to pick up shares.
Needed more n, more critical patients, and a representative age distribution between drug and control arms.
Also thought I heard the new trial would be 1 to 1. Wondering if I heard that right and what the secondary endpoints would be.
Nader seems to be relying on Brian Brothen to help fill quickly. My take is the Mr Brothen did make a huge enrollment difference in November and December. Plus there is more data. So they may be able to fill quickly.
So I see some dark weeks coming where people complain about enrollment and worry about dilution. Good time to pick up shares.
(3)
(0)Scroll down for more posts ▼
